Sensory Evaluation of the Taste of Pediatric Medicines (MEDTASTE)

Monell Chemical Senses Center

Status: Completed

Conditions: Healthy

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT03627351

R01DC011287 (U.S. NIH Grant/Contract)

T24653

Details and patient eligibility

About

The investigators will conduct a systematic study of the sensory perception of a diverse set of commonly used pediatric liquid medications and excipients in tandem with an equally complete genetic analysis of the adult sensory panelists to investigate the relationship between genetic variation and individual differences in the perceived flavor (taste, smell, irritation) of pediatric medicines. The flavor of each medicine and excipient will be measured individually using both cognitively demanding methods unsuitable for young children and simpler measures validated for use by children. Salivary DNA samples will be collected to carry out genome wide association study (GWAS).

Full description

This is a single-site, cross-sectional, repeated measures study of healthy adult panelists which will investigate individual differences in the taste of a diverse set of commonly used pediatric liquid medications (e.g., clindamycin, prednisone, dexamethasone, mercaptopurine, ibuprofen, lopinavir/ritonavir, propylthiouracil) and excipients (e.g., sucrose, citric acid, bitter agents, salt, menthol and other odors) in tandem with genetic analysis. Because the medication given to pediatric patients is the whole liquid formulation (API + excipients), the investigators' approach will be to have panelists taste (without swallowing) what patients taste. Using validated psychophysical tools such as the general labelled magnitude scale (gLMS), the hedonic gLMS, and the hedonic 5-face scale, adults panelists will rate the intensity of the basic tastes, overall intensity, irritation, or palatability (hedonics) of a variety of pediatric drugs (with and without noseclips), along with generally recognized as safe (GRAS) taste and odor stimuli commonly used in basic research and/or as excipients in many liquid formulations These data will establish whether the palatability and flavor of each medicine varies among adult panelists. From these data, the investigators will determine a) whether the dislike of one medicine by a panelist predicts their dislike of another medicine in the same class or medicines with the same excipients; b) whether variation in the flavor and palatability ratings of each medicine relates to variation in genetic polymorphisms, as determined from the GWAS; and c) whether the panelists' palatability ratings of each medicine, as assessed by the simpler hedonic 5-face scale, is significantly related to hedonic gLMS ratings.

Enrollment: 154 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Men and women who are between the ages of 18 and 55 years

Exclusion Criteria include the following:

• For all female participants, a urine pregnancy test will be done on each testing day. Only those with a negative pregnancy test will be allowed to participate in taste testing.
• Smokers will be excluded since it alters flavor perception.
• Potential subjects will be excluded if they are on drugs with potential serious adverse effects that are mediated through CYP450 3A4 since ritonavir is a potent inhibitor of CYP450 3A4 and could lead to elevated levels of the prohibited drugs if swallowed. The prohibited drugs include the following:
• Alfuzosin (Uroxatral; alpha-1-adrenoreceptor antagonist)
• Astemizole (Hismanal; antihistamine)
• Bepridil (Vascor; calcium channel blocker)
• Cerivastatin (Baycol; statin)
• Cisapride (Propulsid; GI motility agent)
• Dronedarone (multaq; anti-arrhythmic)
• Ergotamine (Cafergot, Ergot derivatives)
• Flecainide (Tabocor; anti-arrhythmic)
• Lovastatin (Altoprev; HMG-CoA Reductase Inhibitor)
• Lurasidone (Latuda; antipsychotic)
• Midazolam (Versed; sedative/hypnotic)
• Pimozide (Orap; antipsychotic)
• Ranolazine (Ranexa; anti-anginal)
• Simvastatin (Zocor; statin)
• Terfenadine (Seldane; antihistamine)
• Tinidazole (Tindamax; anti-parasitic)
• Trazodone (Desyrel; antidepressant/sedative)
• Triazolam (Halcion; sedative)
• Warfarin (Coumadin; blood thinner)
• Potential subjects will be excluded if they have had current (within the last 24 hours) use of sildenafil (Viagra), tadalafil (Cialis), and verdenafil (Levitra) are also exclusion criteria. These drugs can be used as needed for erectile dysfunction. They are also used as a daily treatment for pulmonary arterial hypertension. With CYP450 3A4 blockade and current use, hypotension, syncope, and prolonged erection are possible.
• Potential subjects will be excluded if they have known allergies or hypersensitivity reactions to lopinavir, ritonavir, clindamycin, prednisone, dexamethasone, ibuprofen, 6-mercaptopurine, propylthiouracil, or any of the excipients in the liquid formulations to be tested.

Trial design

154 participants in 1 patient group

Healthy Women and Men

Description:

Group of healthy women and men